Everything below concerns preclinical research. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Derived from an angiotensin IV sequence. |
| Appearance | White to off-white powder | Typical for lyophilized research peptides. |
| Solubility | Soluble in dimethyl sulfoxide; sparingly in water | Exact aqueous solubility depends on salt form and purity. |
| Typical storage temperature | -20 °C or below | Desiccated and protected from light for long-term storage. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary in catalog listings. |
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
=== Ribosome-mediated attenuation === In this situation RNA polymerase is dependent on (lagging) ribosome activity; if the ribosome pauses due to insufficient charged tRNA then the anti-terminator structure is favoured. The canonical attenuator example of the trp operon uses this mechanism in E. coli. Similar regulatory mechanisms have been found in many amino acid biosynthetic operons.
Initial letters are used where there is no ambiguity: C cysteine, H histidine, I isoleucine, M methionine, S serine, V valine. No other amino acids in this set begin with each of those letters. Where arbitrary assignment is needed, the structurally simpler amino acids are given precedence: A alanine, G glycine, L leucine, P proline, T threonine. For example, alanine is simpler than arginine or asparagine, the other amino acids starting with "a". F PHenylalanine and R aRginine are assigned by being phonetically suggestive, W tryptophan is assigned based on the double ring being visually suggestive to the bulky letter W, K lysine and Y tyrosine are assigned as alphabetically nearest to their initials L and T (note that U was avoided for its similarity with V, while X was reserved for undetermined or atypical amino acids); for tyrosine the mnemonic tYrosine was also proposed, D aspartate was assigned arbitrarily, with the proposed mnemonic asparDic acid; E glutamate was assigned in alphabetical sequence being larger by merely one methylene –CH2– group, N asparagine was assigned arbitrarily, with the proposed mnemonic asparagiNe; Q glutamine was assigned in alphabetical sequence of those still available (note again that O was avoided due to similarity with D), with the proposed mnemonic Qlutamine.
Mrochen M, Jankov M, Iseli HP, Hafezi F, Seiler T Retinal imaging aberrometry - principles and application of the Tscherning aberrometer, in Wavefront Customized Visual Correction: The Quest for Super Vision II, MacRae S, Krueger RR, Applegate RA, Editors. 2003, Slack Incorporated: New York. 137–43. 8. Hafezi F, Abegg M, Wenzel A, Grimm C, Remé CE Lichtschäden des Auges: ein Überblick, in Risikofaktoren für Augenerkrankungen, Erb C, Flammer J, Editors. 1999, Hans Huber: Bern, Göttingen, Toronto, Seattle. 277–83. 9. Remé CE, Hafezi F, Marti A, Munz K, Reinboth JJ Light damage to retina and pigment epithelium, in The Retinal Pigment Epithelium, current aspects of function and disease, Marmor MF, Wolfensberger T, Editors. 1998, Oxford University Press: Oxford. 563–86. 10. Remé CE, Bush R, Hafezi F, Wenzel A, Grimm C Photostasis and beyond: where adaptation ends, in Photostasis and related phenomena, Williams TP, Thistle AB, Editors. 1998, Plenum Press: New York. 199–206. 11. Hafezi F, Marti A, Steinbach JP, Munz K, Aguzzi A, Remé CE Light-induced retinal degeneration is prevented in mice lacking c-fos, in Degenerative retinal diseases, LaVail MM, Hollyfield JG, Anderson RE, Editors. 1998, Plenum Press: New York. 193–98. 12. Remé CE, Hafezi F, Grimm C, Wenzel A UV- und Lichtschäden des Auges - wie kann man sich schützen?, in Physikalische Therapiemassnahmen in der Dermatologie, Dummer R, Panizzon R, Burg G, Editors. 1997, Blackwell Wissenschaftsverlag: Berlin. 200–09. 13.
=== Dental care === ACE-inhibitors like lisinopril are considered to be generally safe for people undergoing routine dental care, though the use of lisinopril prior to dental surgery is more controversial, with some dentists recommending discontinuation the morning of the procedure. People may present to dental care suspicious of an infected tooth, but the swelling around the mouth may be due to lisinopril-induced angioedema, prompting emergency and medical referral.
== Production and synthesis == γ-Butyrolactone is produced industrially by dehydrogenation of 1,4-butanediol at a temperature of 180–300 °C and atmospheric pressure in the presence of a copper catalyst.
Sources: en.wikipedia.org
Sun, de la Torre & Bibi (2026) study the composition of large mammal faunas in Africa and Eurasia throughout the last 10 million years, finding no evidence of waves of faunal dispersal out of Africa, no evidence that early hominins followed dispersal routes of large herbivores out of Africa, no evidence that dispersal of early hominins into Eurasia coincided with major changes in the functional structure of mammalian communities, and no evidence of signification latitudinal differences of the studied communities. Cantalapiedra et al. (2026) study the diversification trends of African artiodactyls, perissodactyls and proboscideans during the last 23 million years, and interpret the decline of large African herbivores as more likely caused by low speciation rates and by environmental constraints on speciation linked to prolonged aridification of Africa than by elevated extinction rates. Evidence from the study of dental and body mass traits of large herbivores from the Turkana Basin and Tugen Hills, indicating that, unlike individual functional traits of mammals from the studied assemblages, multivariate combinations of traits remained closely aligned with environmental conditions throughout the last 10 million years, is presented by Glöggler et al. (2026); the data and the analytical framework of this study are subsequently reevaluated by Greiner & Dagher (2026), who do not consider the conclusions of the study of Glöggler et al. to be conclusively supported by available data.
== Vaginal atrophy == In post-menopausal women, the walls of the vagina become thinner (atrophic vaginitis). The mechanism for the age-related condition is not yet clear, though there are theories that the effect is caused by decreases in estrogen levels. This atrophy, occurring concurrently with breast atrophy, is consistent with the homeostatic (normal development) role of atrophy in general, as after menopause the body has no further functional biological need to maintain the reproductive system which it has permanently shut down.
=== Organic acid technology === Most modern cars are built with organic acid technology (OAT) antifreeze (e.g., DEX-COOL), or with a hybrid organic acid technology (HOAT) formulation (e.g., Zerex G-05), both of which are claimed to have an extended service life of five years or 240,000 km (150,000 mi). DEX-COOL specifically has caused controversy. Litigation has linked it with intake manifold gasket failures in General Motors' (GM's) 3.1L and 3.4L engines, and with other failures in 3.8L and 4.3L engines. One of the anti-corrosion components presented as sodium or potassium 2-ethylhexanoate and ethylhexanoic acid is incompatible with nylon 6,6 and silicone rubber, and is a known plasticizer. Class action lawsuits were registered in several states of the US, and in Canada, to address some of these claims. The first of these to reach a decision was in Missouri, where a settlement was announced early in December 2007. Late in March 2008, GM agreed to compensate complainants in the remaining 49 states. GM (Motors Liquidation Company) filed for bankruptcy in 2009, which tied up the outstanding claims until a court determines who gets paid. According to the DEX-COOL manufacturer, "mixing a 'green' [non-OAT] coolant with DEX-COOL reduces the batch's change interval to 2 years or 50,000 km (30,000 mi), but will otherwise cause no damage to the engine". DEX-COOL antifreeze uses two inhibitors: sebacate and 2-EHA (2-ethylhexanoic acid), the latter which works well with the hard water found in the United States, but is a plasticizer that can cause gaskets to leak.
Chemical Formula: C24H44O6 HLB Value: 4.3; suitable for water-in-oil (W/O) emulsions. Soluble in warm water and has good dispersibility in organic solvents such as ethanol and ethyl acetate. Physical Form: Amber liquid Fatty acid composition: Oleic acid (C18:1) ≤ 60%; balance primarily linoleic (C18:2), linolenic (C18:3) and palmitic (C16:0) acids. At high concentrations, sorbitan monooleate can increase the viscosity of the emulsion, which can further enhance stability by reducing the movement of dispersed droplets. When combined with other surfactants, especially those with higher HLB values like Tween 80, sorbitan monooleate can contribute to the overall stability of oil-in-water (O/W) emulsions. This combination allows for the creation of emulsifying systems with various HLB values, enabling the emulsification of a wide range of oils and waxes.
Sources: en.wikipedia.org
Faced with the threat of growing German Nazism, Italian fascism, Japanese militarism, and a world war, the Western Allies and the Soviet Union formed an alliance of necessity during World War II. After the Axis powers were defeated, the two most powerful states in the world became the Soviet Union and the United States. Both federations were called the world's superpowers. The underlying geopolitical and ideological differences between the recent allies led to the confrontation known as the Cold War, which lasted from about 1947 to 1991. It began with the second Red Scare and it ended with the fall of the Soviet Union. At the dawn of the new era, the historian John Lewis Gaddis wrote: The new world of the post–Cold War era is likely to have few, if any, of these [Cold War] characteristics: that is an indication of how much things have already changed since the Cold War ended. We are at one of those rare points of 'punctuation' in history at which old patterns of stability have broken up and new ones have not yet emerged to take their place. Historians will certainly regard the years 1989–1991 as a turning point comparable in importance to the years 1789–1794, or 1917–1918, or 1945–1947; precisely what has 'turned,' however, is much less certain. We know that a series of geopolitical earthquakes have taken place, but it is not yet clear how these upheavals have rearranged the landscape that lies before us.
Wheatgrass is the freshly sprouted first leaves of the common wheat plant (Triticum aestivum), used as a food, drink, or dietary supplement. Wheatgrass is served freeze dried or fresh, and so it differs from wheat malt, which is convectively dried. Wheatgrass is allowed to grow longer and taller than wheat malt. Like most plants, wheatgrass contains chlorophyll, amino acids, minerals, vitamins and antioxidant enzymes. Claims about the health benefits of wheatgrass range from providing supplemental nutrition, anti-inflammatory effects, anti-oxiditative effects to having unique curative properties, but there is no good scientific evidence to support these uses.
{\displaystyle {\begin{aligned}{\bar {I}}_{1}&=J^{-2/3}~I_{1}~;~~I_{1}=\lambda _{1}^{2}+\lambda _{2}^{2}+\lambda _{3}^{2}~;~~J=\det({\boldsymbol {F}})\\{\bar {I}}_{2}&=J^{-4/3}~I_{2}~;~~I_{2}=\lambda _{1}^{2}\lambda _{2}^{2}+\lambda _{2}^{2}\lambda _{3}^{2}+\lambda _{3}^{2}\lambda _{1}^{2}\end{aligned}}}
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.
No major regulatory agency has approved dihexa as a therapeutic product. Human safety and efficacy data are limited. Its sale as a research chemical does not constitute approval for medical use.
Some animal and cell studies report synaptic or cognitive effects, which has led to nootropic framing online. These findings are preliminary and have not been confirmed in robust human trials. The term nootropic is not a regulatory category.
Typical storage is at -20 °C in a desiccated container protected from light. Repeated freeze-thaw cycles are usually minimized to reduce degradation. Specific conditions should follow the supplier’s documentation.